EUVIMEDEUVIMED entdecken
Crossref

FDA Okays First Drug for Scarring From Fatty Liver Disease

Emily Harris

JAMA · 2024

DOI: 10.1001/jama.2024.5154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Emily Harris. Hauptthemen laut MEDLINE: Drug Approval, Non-alcoholic Fatty Liver Disease, Anti-Inflammatory Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalNon-alcoholic Fatty Liver DiseaseAnti-Inflammatory AgentsHumansCicatrixUnited StatesUnited States Food and Drug AdministrationLiver CirrhosisReceptors, Thyroid Hormone

Substanzen

Anti-Inflammatory AgentsReceptors, Thyroid Hormone

Zitieren

APA

Harris, E. (2024). FDA Okays First Drug for Scarring From Fatty Liver Disease. JAMA. https://doi.org/10.1001/jama.2024.5154

Vancouver

Harris E. FDA Okays First Drug for Scarring From Fatty Liver Disease. JAMA. 2024. doi:10.1001/jama.2024.5154

BibTeX
@article{Harris2024,
  author = {Harris, Emily},
  title = {FDA Okays First Drug for Scarring From Fatty Liver Disease},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2024.5154}
}
Kostenlos starten →